<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03126201</url>
  </required_header>
  <id_info>
    <org_study_id>333</org_study_id>
    <nct_id>NCT03126201</nct_id>
  </id_info>
  <brief_title>Predictors of Disease Progression in Primary Focal Segmental Glomerulosclerosis</brief_title>
  <official_title>Predictors of Disease Progression in Patients With Primary Focal Segmental Glomerulosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Focal segmental glomerulosclerosis (FSGS) is one of the most common primary glomerular
      diseases leading to end stage renal disease. In this study, our aim is to evaluate the
      effects of histopathological, clinical, and laboratory features of patients with primary FSGS
      on the disease progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Focal segmental glomerulosclerosis (FSGS) is one of the most common primary glomerular
      diseases leading to end stage renal disease worldwide. Numerous studies have been conducted
      in order to identify the etiology of this debilitating disease. Beyond the etiological
      research, however, few studies managed to demonstrate the possible predictors of disease
      progression in patients. Therefore, we aim to evaluate the effects of histopathological,
      clinical, and laboratory features of patients with primary FSGS on the disease progression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in kidney function and/or progression to end stage renal disease</measure>
    <time_frame>5-10 years</time_frame>
    <description>At least a fifty-percent reduction in baseline estimated glomerular filtration rate (eGFR) or development of kidney failure, which was defined as a category G5 CKD (eGFR &lt;15 ml/min/1.73 m2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission</measure>
    <time_frame>5-10 years</time_frame>
    <description>Proteinuria below 0.5 g/24h and an eGFR of ≥60 ml/min per 1.73 m2 (or a return of ±15% of baseline values in those with eGFR &lt;60 ml/min per 1.73 m2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial remission</measure>
    <time_frame>5-10 years</time_frame>
    <description>Absence of complete remission, proteinuria reduction of &gt;50% (and a proteinuria value of &lt;3 g/24h in patients with nephrotic range proteinuria at baseline), and stabilization (±25%) or improvement in renal function.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">86</enrollment>
  <condition>Glomerulonephritis</condition>
  <condition>Focal Segmental Glomerulosclerosis</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <description>Patients with biopsy-proven primary focal segmental glomerulosclerosis.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with biopsy-proven primary focal segmental glomerulosclerosis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with biopsy-proven primary focal segmental glomerulosclerosis.

          -  Patients who have a renal biopsy available for reviewing including 8 or more
             glomeruli.

          -  Patients who have been followed-up for at least 6 months or have progressed to primary
             outcome regardless the duration of follow-up.

        Exclusion Criteria:

          -  Patients who have secondary focal segmental glomerulosclerosis attributable to any
             other condition (e.g., obesity, HIV, relevant drug exposure).

          -  Patients who have a genetic mutation or variation creating a tendency for developing
             focal segmental glomerulosclerosis.

          -  Patients who are unwilling or unable to consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yasar Caliskan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>D'Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med. 2011 Dec 22;365(25):2398-411. doi: 10.1056/NEJMra1106556. Review.</citation>
    <PMID>22187987</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2017</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul University</investigator_affiliation>
    <investigator_full_name>Yasar Caliskan</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>focal segmental glomerulosclerosis</keyword>
  <keyword>disease progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Progression</mesh_term>
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

